B
0.420
0.04 (10.53%)
| Penutupan Terdahulu | 0.380 |
| Buka | 0.370 |
| Jumlah Dagangan | 226 |
| Julat 52 Minggu |
| Margin Keuntungan | -119.41% |
| Margin Operasi (TTM) | -87.08% |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 12,047.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 40.20% |
| Nisbah Semasa (MRQ) | 1.15 |
| Aliran Tunai Operasi (OCF TTM) | -7.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.29 M |
| Pulangan Atas Aset (ROA TTM) | -69.78% |
| Pulangan Atas Ekuiti (ROE TTM) | -151.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | bioAffinity Technologies, Inc. | - | - |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | NA |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | 0.00 |
|
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |